Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.

A series of novel C,N-cyclometalated benzimidazole ruthenium(II) and iridium(III) complexes of the types [(η(6)-p-cymene)RuCl(κ(2)-N,C-L)] and [(η(5)-C5Me5)IrCl(κ(2)-N,C-L)] (HL = methyl 1-butyl-2-arylbenzimidazolecarboxylate) with varying substituents (H, Me, F, CF3, MeO, NO2, and Ph) in the R4 position of the phenyl ring of 2-phenylbenzimidazole chelating ligand of the ruthenium (3a-g) and iridium complexes (4a-g) have been prepared. The cytotoxic activity of the new ruthenium(II) and iridium(III) compounds has been evaluated in a panel of cell lines (A2780, A2780cisR, A427, 5637, LCLC, SISO, and HT29) in order to investigate structure-activity relationships. Phenyl substitution at the R4 position shows increased potency in both Ru and Ir complexes (3g and 4g, respectively) as compared to their parent compounds (3a and 4a) in all cell lines.

[General health, reproductive health and internet. A pathfinder for French speaking adolescents].

Internet offers interesting information concerning health issues. This paper presents a selection of french sites destined for youth about general and reproductive health. Pediatricians could recommend them to their adolescent patients.

An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency.

The present study was designed to compare the safety and efficacy of a combination of Ruscus aculeatus, hesperidin methyl chalcone, and ascorbic acid (Cyclo 3 Fort) versus that of hydroxyethyl rutoside in treatment of chronic venous lymphatic insufficiency. This open-label, randomized multicenter study was conducted on outpatients treated for 90 days. The patients were from three different regions of Argentina.

An open-label, randomised multicentre study comparing the efficacy and safety of CYCLO 3 FORT versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency.

Background: The present study was designed to compare the safety and efficacy of a combination of Ruscus aculeatus, hesperidin methyl chalcone and ascorbic acid (CYCLO 3 FORT) versus that of hydroxyethyl rutoside in the treatment of chronic venous lymphatic insufficiency.

Methods: This open-label, randomised multicentre study was conducted on outpatients treated for 90 days. The patients were from three different regions of Argentina.

[Treatment of congenital chloride diarrhea with prostaglandin synthetase inhibitor (author's transl)].

In a patient with congenital chloride diarrhea, the hyperreninemia, hyperaldosteronism, hypokaliemia and hypokaliuria diminished during treatment with prostaglandin synthetase inhibitor. These findings suggest that probably prostaglandins stimulate renin-aldosterone system in congenital chloride diarrhea.